About Hinova
Our Company
Executive Team
Partnerships
Contact Us
Innovation
Therapeutic Areas
R&D Platforms
Pipeline & Programs
Collaboration
News
Press Releases
Careers
Working at Hinova
Employee Benefits
Open Positions
EN
CH
About Hinova
Our Company
Executive Team
Partnerships
Contact Us
Innovation
Therapeutic Areas
R&D Platforms
Pipeline & Programs
Collaboration
News
Press Releases
Careers
Working at Hinova
Employee Benefits
Open Positions
Integrity,Innovation,Reliability,Responsibility
Press Releases
Home
News
Press Releases
Media and Public Relations
media@hinovapharma.com
2023
2022
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
2023.02.06
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
2022.10.31
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
2022.01.20
加载更多